Nightingale Health Group's Half-year report 1 July 2024 - 31 December 2024 (unaudited) Nightingale Health's half-year report: International expansion continues in Southeast Asia and the United States ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...

Grifols revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential ...

Research Group Biotechnology and Biomedicine, Peter-Debye-Institute for Soft Matter Physics, Leipzig University, Linnéstraße 5, 04103 Leipzig, Germany ...

Introduction: Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB), a disease with a severe global burden. The intractability of Mtb has prevented the identification of clear ...

Our albumin portfolio grew strongly by 9%, driven by exceptional performance in China. Hemophilia growth was 11%, with IDELVION up 6%. Contributing to the growth in hemophilia is our gene therapy ...